NEWS

NEWS 2024

News Highlights

Check this page for recent news from Appili Therapeutics.

Appili Therapeutics Announces Results of Special Meeting of Shareholders

Read More

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Read More

Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024

Read More

Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders

Read More

Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

Read More

Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt

Read More

Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025

Read More

Appili Therapeutics Announces Second Amendment to Arrangement Agreement

Read More

Appili Therapeutics Announces Amendment to Arrangement Agreement and Increase to Bridge Loan

Read More

Appili Therapeutics Reports Fiscal Year 2024 Financial and Operational Results

Read More

Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.

Read More

Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.

Read More

Researchers Publish Manuscript on the Prevention and Emergency Response to Tularemia Outbreaks

Read More

Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024

Read More